Instituto Nacional de Infectologia Evandro Chagas
Rio de Janeiro, 21040-360, Brazil
Location status: Recruiting
NCT Number: NCT07772791
This study will create and follow an online cohort of sexual and gender minorities in Brazil to better understand the use of HIV prevention and treatment strategies, particularly pre-exposure prophylaxis (PrEP) and antiretroviral treatment (ART). Participants will complete online questionnaires at the beginning of the study and every three months for one year to provide information about medication use and adherence, sexual behaviors, HIV prevention and testing, sexually transmitted infections, mental health, and experiences of discrimination in health services.
Participants who are using PrEP or ART and agree to take part in the intervention will be randomly assigned to receive either a digital intervention or no digital intervention. The digital intervention will consist of weekly WhatsApp messages for six months, including reminders and information intended to support adherence to PrEP or ART.
The main question of the study is whether weekly WhatsApp messages can improve adherence to PrEP or ART among sexual and gender minorities in Brazil. The study hypothesis is that participants who receive the digital intervention will have higher adherence to PrEP or ART than participants who do not receive the intervention.
Interested in participating?
Request Info18 year and older
Male
Interventional
Not applicable
Rio de Janeiro, 21040-360, Brazil
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
male sex assigned at birth and identifying as a man, travesti, transgender person, or non-binary person; age ≥18 years; residing in Brazil; access to the internet; and self-reporting sex with a man in the past 12 months.
Exclusion criteria
incorrectly answering the attention-check questions; and incomplete responses, defined as not reaching the end of the screening questionnaire
Participants randomized to the intervention arm will receive weekly WhatsApp messages for 6 months designed to support adherence to pre-exposure prophylaxis (PrEP) or antiretroviral therapy (ART). Messages will include medication reminders and brief, standardized information related to HIV prevention and treatment. Messages will be delivered through a scheduled automated system.
Time frame: Baseline and Months 3, 6, 9, and 12
Medication adherence will be assessed using a visual analog scale in which participants report the percentage of prescribed PrEP or ART doses taken during the previous 30 days, from 0% to 100%. Participants reporting adherence greater than 95% will be classified as adherent. The primary analysis will compare the proportion of participants classified as adherent between the weekly WhatsApp intervention and control groups over follow-up.
Time frame: Baseline and Months 3, 6, 9, and 12
Self-reported adherence to PrEP during the previous 30 days, measured using a 0% to 100% visual analog scale. Participants reporting adherence greater than 95% will be classified as adherent. Adherence will be evaluated over follow-up and compared between intervention and control groups among participants using PrEP.
Contact information is provided by the study sponsor or research team.
Oswaldo Cruz Foundation
Other
Online Cohort of Sexual and Gender Minorities: Evaluating the Effect of Digital Interventions on the Uptake and Adherence to HIV Pre-Exposure Prophylaxis and Antiretroviral Treatment
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07473778
Blood-Borne Infections, Communicable Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT06388109
Blood-Borne Infections, Communicable Diseases
Van Nuys, California, United States
View Trial DetailsNCT07728123
Blood-Borne Infections, Communicable Diseases
Tampa, Florida, United States
View Trial DetailsNCT07393659
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Durban, KwaZulu-Natal, South Africa
View Trial Details